Salamanca

• A study to test an oral medicine, belumosudil, in combination with corticosteroids in participants at least 12 years of age with newly diagn … Ended recruitment
  2023-505394-32-00 5 2025-02-06 chronic graft versus host disease
• A clinical trial to learn about the effects of YTB323 in people with difficult-to-treat severe inflammatory myopathies (IIM) Ended recruitment
  2024-514137-38-00 4 2025-02-04 Severe refractory idiopathic inflammatory myopathies (IIM)
• A randomized, double-blind, parallel group, placebo-controlled multicenter study to evaluate efficacy, safety and tolerability of ianalumab … Ended recruitment
  2024-511933-36-00 4 2025-01-02 Diffuse cutaneous systemic sclerosis (dcSSc)
• Research study on the use of capivasertib together with fulvestrant in patients with advanced breast cancer who have relapsed/progressed to … Ended recruitment
  2024-513952-13-00 5 2025-01-02 HR+ / HER2- advanced breast cancer
• Study to evaluate the use of durvalumab in combination with platinum-based chemotherapy followed by durvalumab with olaparib as first-line t … Ended recruitment
  2024-514728-17-00 11 2024-12-30 Advanced or recurrent endometrial cancer
• A Phase 3 Study of Barzolvolimab in Patients with Chronic Spontaneous Urticaria (EMBARQ – CSU1) Ended recruitment
  2024-513208-32-00 5 2024-12-16 Chronic Spontaneous Urticaria
• Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti-HER2 Therapy + Endocrine Therapy vs. Anti- … Ended recruitment
  2024-513540-29-00 5 2024-11-07 Breast Cancer
• A Randomized Phase IIb Study, Evaluating Efficacy of Salvage Therapy with Brentuximab Vedotin-ESHAP vs ESHAP in Patients with Relapsed / Ref … Ended recruitment
  2024-516149-38-00 4 2024-10-29 Hodgkin Lymphoma
• SPOTLIGHT 204: A Multicenter, Phase 2b, open-label, non-randomized, clinical trial to evaluate safety, tolerability and preliminary efficacy … Ended recruitment
  2024-511801-51-00 4 2024-10-24 Basal cell carcinoma
• INCA34176-254: A Phase 2, Open-Label, Randomized, Multicenter Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ru … Ended recruitment
  2022-502168-19-00 4 2024-10-22 chronic graft-versus-host disease
• Ph2 Study of MK-3475A in Hematologic Malignances in Participants with Relapsed or Refractory Classical Hodgkin Lymphoma or Relapsed or Refra … Ended recruitment
  2024-510969-42-00 4 2024-09-30 Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapse
• A Phase III study to investigate the efficacy and safety of anifrolumab in adults with chronic and/or subacute cutaneous lupus erythematosus Ended recruitment
  2023-503692-24-00 5 2024-09-25 Cutaneous Lupus Erythematosus
• A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended recruitment
  2023-509190-23-00 5 2024-09-03 Atherosclerotic Cardiovascular Disease Elevated lp(a)
• A multicenter, open-label, randomized, phase 2 study of venetoclax and azacitidine plus cusatuzumab versus venetoclax and azacitidine alone … Ended recruitment
  2024-510991-19-00 4 2024-08-14 Acute myeloid leukemia
• A Study to Compare the Efficacy and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants with Previously Untreated High- … Ended recruitment
  2023-510178-15-00 5 2024-07-31 High-risk Large B-cell Lymphoma
• A phase II, open-label, multicenter study of orally administered RVU120 for the treatment of anemia in patients with lower-risk myelodysplas … Ended recruitment
  2023-509947-29-00 4 2024-07-18 Anemia in patients with very low, low or intermediate risk myelodyspla
• Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell … Ended recruitment
  2023-503594-38-00 1 2024-07-15 Select B-Cell malignancies.
• An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Seralutinib Orally Inhaled for the Treatment of Pulmonary Arte … Ended recruitment
  2023-506334-75-00 5 2024-07-12 Pulmonary Arterial Hypertension
• A Phase 3 Double-blind, Randomized, Placebo-controlled Trial to Evaluate the Efficacy and Safety of AR1001 in Participants with Early Alzhei … Ended recruitment
  2023-508306-15-00 5 2024-06-26 Alzheimer’s Disease
• A Phase 3 study of Etentamig vs Standard Available Therapies in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM) (3L+ RRMM Monot … Ended recruitment
  2023-506668-15-00 5 2024-06-17 Relapsed or Refractory Multiple Myeloma (RRMM)
• Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended recruitment
  2023-508235-31-00 5 2024-06-17 Atopic Dermatitis
• Multicentric phase II trial to evaluate the efficacy and safety of Ibrutinib in combination with rituximab in patients with indolent clinica … Ended recruitment
  2024-512370-94-00 4 2024-06-13 Mantle Cell Lymphoma
• A Phase 1 Randomized, Open Label Pharmacokinetic Comparability Study Comparing Pre- and Post-change Teclistamab in Participants with Relapse … Ended recruitment
  2023-508426-10-00 3 2024-06-03 Relapsed/Refractory Multiple Myeloma
• A study to evaluate the efficacy and safety of JCAR017 in adult subjects with a type of cancer that affects B-cells, a type of white blood c … Ended recruitment
  2024-510966-18-00 4 2024-06-03 Relapsed or refractory indolent B-cell Non-Hodgkin Lymphoma (NHL)

Showing 217–240 of 470 trials